Teva Pharmaceutical Industries Ltd. has acquired Allergan Generics for $40.5 billion. Upon closing, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion. The transaction was unanimously approved by the boards of both companies and is expected to close in the first quarter of 2016. This acquisition brings together two leading generics businesses and will create a leader in the INN and branded generics industry. When combined with Teva’s strong generics ...